Last reviewed · How we verify
EIDD-2801
At a glance
| Generic name | EIDD-2801 |
|---|---|
| Also known as | molnupiravir, MK-4482, Molnupiravir |
| Sponsor | Ridgeback Biotherapeutics, LP |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- AGILE (Early Phase Platform Trial for COVID-19) (PHASE1, PHASE2)
- A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011) (PHASE1)
- A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016) (PHASE1)
- A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003) (PHASE1)
- The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) (PHASE2)
- Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 (PHASE2)
- COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EIDD-2801 CI brief — competitive landscape report
- EIDD-2801 updates RSS · CI watch RSS
- Ridgeback Biotherapeutics, LP portfolio CI